Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [

Molecular imaging Neuroendocrine tumors Positron emission tomography-computed tomography Somatostatin

Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
20 May 2024
Historique:
received: 27 11 2023
accepted: 18 04 2024
revised: 27 02 2024
medline: 21 5 2024
pubmed: 21 5 2024
entrez: 20 5 2024
Statut: aheadofprint

Résumé

Somatostatin receptor positron emission tomography/computed tomography (SSTR-PET/CT) using [ Four readers assessed [ The ICC analysis on the inter-reader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 85%), overall scan score (ICC ≥ 90%), and the decision to recommend PRRT (ICC ≥ 85%) showed excellent agreement. However, significant differences were observed in recommending PRRT among experienced readers (ER) (p = 0.020) and inexperienced readers (IR) (p = 0.004). Compartment-based analysis demonstrated good to excellent inter-reader agreement for most organs (ICC ≥ 74%), except for lymph nodes (ICC ≥ 53%). SSTR-RADS 1.0 represents a highly reproducible and consistent framework system for stratifying SSTR-targeted PET/CT scans, even using the novel SSTR-ligand [ SSTR-RADS 1.0 is a consistent framework for categorizing somatostatin receptor-targeted PET/CT scans when using [ SSTR-RADS 1.0 is a valuable tool for managing patients with NET. SSTR-RADS 1.0 categorizes patients with showing strong agreement across diverse reader expertise. As an alternative to [

Identifiants

DOI: 10.1007/s00330-024-10788-3 PMID: 38769164
pubmed: 38769164
doi: 10.1007/s00330-024-10788-3
pii: 10.1007/s00330-024-10788-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with
doi: 10.1007/s00259-017-3728-y pubmed: 28547177
Poeppel TD, Binse I, Petersenn S et al (2011)
doi: 10.2967/jnumed.111.091165 pubmed: 22072704
Sundin A, Arnold R, Baudin E et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 105:212–244
doi: 10.1159/000471879 pubmed: 28355596
Lindner S, Wängler C, Bailey JJ et al (2020) Radiosynthesis of [
doi: 10.1038/s41596-020-00407-y pubmed: 33230332
Gower-Fry L, Kronemann T, Dorian A et al (2021) Recent advances in the clinical translation of silicon fluoride acceptor (SiFA)
Litau S, Niedermoser S, Vogler N et al (2015) Next generation of SiFAlin-based TATE derivatives for PET imaging of SSTR-positive tumors: influence of molecular design on in vitro SSTR binding and in vivo pharmacokinetics. Bioconjug Chem 26:2350–2359
doi: 10.1021/acs.bioconjchem.5b00510 pubmed: 26420336
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335
doi: 10.1001/jamaoncol.2017.0589 pubmed: 28448665 pmcid: 5824320
Mittra ES (2018) Neuroendocrine tumor therapy:
doi: 10.2214/AJR.18.19953 pubmed: 29949416
Haug AR (2020) PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res 10:35
doi: 10.1186/s13550-020-00623-3 pubmed: 32296955 pmcid: 7158965
Strosberg JR, Caplin ME, Kunz PL et al (2021)
doi: 10.1016/S1470-2045(21)00572-6 pubmed: 34793718
Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of
doi: 10.1056/NEJMoa1607427 pubmed: 28076709 pmcid: 5895095
Werner RA, Solnes LB, Javadi MS et al (2018) SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework. J Nucl Med 59:1085–1091
doi: 10.2967/jnumed.117.206631 pubmed: 29572257
Grawe F, Ebner R, Geyer T et al (2023) Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol 33:3416–3424
doi: 10.1007/s00330-023-09518-y pubmed: 36964768 pmcid: 10121493
Werner RA, Derlin T, Rowe SP et al (2020) High interobserver agreement for the standardized reporting system SSTR-RADS 1.0 on somatostatin receptor PET/CT. J Nucl Med. https://doi.org/10.2967/jnumed.120.245464:jnumed.120.2454
Leupe H, Ahenkorah S, Dekervel J et al (2023)
doi: 10.2967/jnumed.123.265622 pubmed: 37169533
Wängler C, Waser B, Alke A et al (2010) One-step
doi: 10.1021/bc100316c pubmed: 21082773
Blok S, Wängler C, Bartenstein P, Jurkschat K, Schirrmacher R, Lindner S (2023) Good practices for the automated production of
doi: 10.1186/s41181-023-00215-1 pubmed: 37819534 pmcid: 10567618
Gabriel M (2018) Radiopeptidtherapie—der „Mustang“ in der therapie von neuroendokrinen tumoren des gastroentero-pankreatischen systems? J Klin Endokrinol Stoffwechsel 11:81–85
doi: 10.1007/s41969-018-0034-7
Cicchetti D (1994) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instrument in psychology. Psychol Assess 6:284–290
doi: 10.1037/1040-3590.6.4.284
Diedenhofen B, Musch J (2016) cocron: a web interface and R package for the statistical comparison of Cronbach’s alpha coefficients. Int J Internet Sci 2016:51–60
Campbell I (2007) Chi-squared and Fisher–Irwin tests of two-by-two tables with small sample recommendations. Stat Med 26:3661–3675
doi: 10.1002/sim.2832 pubmed: 17315184
Niedermoser S, Chin J, Wängler C et al (2015) In vivo evaluation of
doi: 10.2967/jnumed.114.149583 pubmed: 25977461
Cives M, Strosberg J (2017) Radionuclide therapy for neuroendocrine tumors. Curr Oncol Rep 19:9
Hope TA, Abbott A, Colucci K et al (2019) NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with
doi: 10.2967/jnumed.118.230607 pubmed: 31263080
Zandee WT, Merola E, Poczkaj K et al (2022) Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. Eur J Cancer Care (Engl) 31:e13639
doi: 10.1111/ecc.13639 pubmed: 35735226
Werner RA, Hartrampf PE, Fendler WP et al (2023) Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol 84:491–502
doi: 10.1016/j.eururo.2023.06.008 pubmed: 37414701
Seifert R, Emmett L, Rowe SP et al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83:405–412
doi: 10.1016/j.eururo.2023.02.002 pubmed: 36935345
Ilhan H, Lindner S, Todica A et al (2020) Biodistribution and first clinical results of
doi: 10.1007/s00259-019-04501-6 pubmed: 31492994
Husband JE (2002) CT/MRI of nodal metastases in pelvic cancer. Cancer Imaging 2:123–129
pmcid: 4448593
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K (2016) The epidemiology of metastases in neuroendocrine tumors Int J Cancer 139:2679–2686
doi: 10.1002/ijc.30400 pubmed: 27553864
Grawe F, Rosenberger N, Ingenerf M et al (2023) Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Cancer Imaging 23:41
doi: 10.1186/s40644-023-00556-9 pubmed: 37098632 pmcid: 10131442
An JY, Unsdorfer KML, Weinreb JC (2019) BI-RADS, C-RADS, CAD-RADS, LI-RADS, lung-RADS, NI-RADS, O-RADS, PI-RADS, TI-RADS: reporting and data systems. Radiographics 39:1435–1436
doi: 10.1148/rg.2019190087 pubmed: 31498744
Werner RA, Bundschuh RA, Bundschuh L et al (2019) Novel structured reporting systems for theranostic radiotracers. J Nucl Med 60:577–584
doi: 10.2967/jnumed.118.223537 pubmed: 30796171 pmcid: 6495242
Unterrainer M, Lindner S, Beyer L et al (2021) PET imaging of meningioma using the novel SSTR-targeting peptide
doi: 10.1097/RLU.0000000000003607 pubmed: 33782306
Ilhan H, Todica A, Lindner S et al (2019) First-in-human
doi: 10.1007/s00259-019-04448-8 pubmed: 31352578

Auteurs

R Ebner (R)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. ricarda.ebner@med.uni-muenchen.de.
ORCID: 0009-0001-0851-0094

A Lohse (A)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.

M P Fabritius (MP)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.

J Rübenthaler (J)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.

C Wängler (C)

Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.

B Wängler (B)

Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.
Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany.

R Schirrmacher (R)

Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, Canada.

F Völter (F)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

H P Schmid (HP)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

L M Unterrainer (LM)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

O Öcal (O)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.

A Hinterberger (A)

DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Heidelberg, Germany.

C Spitzweg (C)

Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.
Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.

C J Auernhammer (CJ)

Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.
Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.

T Geyer (T)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.

J Ricke (J)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.

P Bartenstein (P)

Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

A Holzgreve (A)

Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

F Grawe (F)

Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Heidelberg, Germany.
Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Classifications MeSH